MedTrace Logo

Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD.

NCT02321839 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2019-08-20

No results posted yet for this study

Summary

To evaluate the visual outcome, number of injections and visits, and the effect of mental status of a treat and extend regimen in managing neovascular age-related macular degeneration with intravitreal ranibizumab.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

DRUG

Intraviteal Ranibizumab 0.5mg

Intraviteal Ranibizumab 0.5mg

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Nagoya City University

    lead OTHER

Principal Investigators

  • Yuichiro Ogura · Nagoya City Univsersity

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2019-03-31
Completion
2019-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02321839 on ClinicalTrials.gov